The loss of oligodendrocytes after stroke is one of the major causes of secondary injury. Glial-restricted progenitors (GRPs) have remylenating potential after intraparenchymal cerebral transplantation. The intraarterial (IA) injection route is an attractive gateway for global brain delivery, but, after IA infusion, naive GRPs fail to bind to the cerebral vasculature. The aim of this study was to test whether overexpression of Very Late Antigen-4 (VLA-4) increases endothelial docking and cerebral homing of GRPs in a stroke model. Mouse GRPs were co-transfected with DNA plasmids encoding VLA-4 subunits (a4, b1). The adhesion capacity and migration were assessed using a microfluidic assay. In vivo imaging of the docking and homing of IA-infused cells was performed using two-photon microscopy in a mouse middle cerebral artery occlusion (MCAO) model. Compared to naïve GRPs, transfection of GRPs with VLA-4 resulted in >60% higher adhesion (p < 0.05) to both purified Vascular Cell Adhesion Molecule-11 (VCAM-11) and TNFa-induced endothelial VCAM-1. VLA-4 þ GRPs displayed a higher migration in response to a chemoattractant gradient. Following IA infusion, VLA-4 þ GRPs adhered to the vasculature at three-fold greater numbers than naïve GRPs. Multi-photon imaging confirmed that VLA-4 overexpression increases the efficiency of GRP docking and leads to diapedesis after IA transplantation. This strategy may be further exploited to increase the efficacy of cellular therapeutics.
Introduction
Stroke is a leading cause of long-term, severe disability worldwide and, to date, most patients cannot receive effective treatment. 1, 2 Stroke usually originates from the sudden occlusion of a vessel carrying blood to the brain, resulting in an almost immediate loss of oxygen and energy supply, 3, 4 and, depending on the occlusion site, the lesion can encompass the white or gray matter, or both. 5 Oligodendrocyte survival and preservation of myelin integrity is critical to normal axonal function. However, the vulnerability of oligodendrocytes to ischemic injury has been demonstrated in numerous in vitro and in vivo studies. [6] [7] [8] [9] [10] The first signs of oligodendrocyte destruction, as measured by the degradation of basic myelin protein (MBP), is visible as soon as 24 h after stroke onset, 11 followed by a massive loss of oligodendrocytes at 48 h. 12 This loss and dysfunction of oligodendrocytes can cause significant secondary axonal injury. 13 Recent evidence suggests that stem cell-based therapy is a viable option for the restoration of destroyed oligodendrocytes. For instance, transplantation of oligodendrocyte progenitors can lead to improved myelination in animal models of multiple sclerosis 14 or spinal cord transaction. 15 Glial-restricted progenitors (GRPs) are a viable source of highly therapeutic myelinating oligodendrocytes, and, following transplantation into the focally demyelinated spinal cord of adult rats or into the brain of neonatal dysmyelinated shiverer mice, 16, 17 GRPs can migrate extensively and differentiate into mature oligodendrocytes. However, the efficiency and safety of GRP delivery into the injured brain, including transient ischemia, remains unknown.
Intraparenchymal injection, although used frequently in (pre-)clinical studies, is invasive and results in a relatively small biodistribution area, which represents a significant drawback when targeting large lesions, including those occurring in stroke. Intravenous (IV) cell delivery is an attractive alternative and is being extensively used in preclinical [18] [19] [20] and clinical 21, 22 settings for stroke treatment. Although IV injection is less invasive, most of the transplanted cells are trapped in the filtering organs, including the lung, liver, spleen, and kidney. 23, 24 As a result, only a small fraction of injected cells reaches the brain. Less conventional cell delivery methods, such as intraperitoneal, 25 intracardiac, 26 and intranasal, 27 have been used, with minimal success, thus failing to justify their broad application. However, a promising yet challenging administration route is intraarterial (IA) injection. Transplantation of cells directly into the artery has the advantage of selectively targeting cells to large areas of the injured brain, bypassing the peripheral filtering organs. 28, 29 While intraarterial infusion of large-size mesenchymal stem cells may lead to complications, 30 ,31 the delivery of even large quantities of small-size GRPs is safe. 32 The potential clinical use of IA injection requires that cells effectively bind to the brain endothelium, as they otherwise would pass through the brain and ultimately be deposited in the filtering organs, as in the case of IV injection.
To ensure effective endothelial capture, injected cells must express key integrins that facilitate their binding with endothelial counterparts. The integrin Very Late Antigen-4 (VLA-4, a heterodimer of integrin a4 and b1) and its ligand Vascular Cell Adhesion Molecule-1 (VCAM-1) is a well-characterized receptor-ligand pair involved in leukocyte trafficking, including cell diapedesis into the brain parenchyma. 33 Since increased VCAM-1 expression on the endothelium has been detected following stroke injury, 34, 35 VLA-4 may be potentially exploited as a docking molecule on the cell membrane. Indeed, neural stem cells enriched for VLA-4 expression display enhanced homing to the infarcted brain. 36 Native GRPs do not express VLA-4; however, VLA-4 expression can be induced via genetic engineering. As proof-of-principle, we showed previously that overexpression of VLA-4 in immortalized GRPs can be successfully used to enhance cerebral endothelial binding in an LPS-induced inflammatory brain model. 37 In this study, we developed a multi-faceted platform where the interaction between VLA-4 þ GRPs and VCAM-1 was first assessed in vitro using microfluidic assays to measure cell binding under shear flow conditions. Moreover, we demonstrate here efficient IA delivery and diapedesis of primary VLA-4 þ GRPs to the ischemia-injured brain parenchyma in vivo, as demonstrated by intravital two-photon microscopy (2-PM).
Materials and methods

Derivation and maintenance of GRPs
Primary mouse GRPs were isolated from the brain of E13 mouse embryos as described. 38 Cells were maintained in Dulbecco's modified Eagle's medium, nutrient mixture F-12 (Life Technologies), supplemented with basic-FGF (basic fibroblast growth factor), B-27, and N2 (Life Technologies), seeded on poly-L-lysine (PLL)/ laminin (Sigma)-coated dishes, and cultured in 5% CO 2 and ambient oxygen for up to three passages.
Cell labeling
Native GRPs and VLA4
þ GRPs were labeled with the fluorescent dye CellTracker TM Green CMFDA (Life Technologies). Cells were incubated at 37 C with 25 mM CMFDA for 30 min. After that time, cells were washed 3 times with PBS and resuspended in PBS at the required concentration.
VLA-4 transfection
Three days prior to cell infusion, GRPs were seeded at a density of 1 Â 10 5 cells/cm 2 and co-transfected with the a4 and b1 subunits of VLA-4 integrin (GeneCopoeia, 2,4 ng/mL) using Lipofectamine 2000 (Life Technologies, 4 mL/mL). VLA-4 expression was confirmed with immunohistochemical staining for each integrin subunit (human integrin alpha 4/CD49d: R&D Systems; integrin b1 (N-20): Santa Cruz Biotechnology) and with RT-PCR. On the day of transplantation, cells were harvested using Accutase (Sigma), and resuspended in PBS at 2 Â 10 6 cells/ml.
Differentiation assay
VLA-4-transfected GRPs were seeded in 24-well plates at a density of 1 Â 10 4 cells/cm 2 . Forty-eight hours after transfection, the maintenance medium was supplemented with Triiodo-L-Thyronine T3 (Sigma, 40 mg/ml) to induce oligodendrocyte differentiation. After 6 days of culture, cells were fixed with 4% paraformaldehyde (PFA) for immunocytochemistry (anti-myelin basic protein (MBP), Santa Cruz) or collected for RT-PCR (MBP, Olig2, glial fibrillary acid protein (GFAP)).
RT-PCR assay
Cellular mRNA was isolated from the cells using Trizol according to the manufacturer's instructions (BioRad). For cDNA synthesis, a RNA-to-cDNA Reverse Transcriptase Kit (Ambion) was used. Primers for the integrin subunits a4 and b1, as well as for other selected genes (MBP, Olig2, and GFAP), were designed using Primer3 and Blast software.
Microfluidic assays
Flow-based adhesion assays were performed in a microfluidic device, as previously described. 39, 40 Pure VCAM-1 or endothelial cells were used as a substrate for this flow-based adhesion assay. The dimensions of the microchannels were L Â W Â H ¼ 2000 Â 500 Â 20 mm (VCAM1-coated) or 2000 Â 500 Â 40 mm (HBECcoated). A shear stress of 1 dyn/cm 2 was used throughout all experiments. On the day of the experiment, 50 ml of 1 Â 10 6 cells/ml (naı¨ve GRPs or VLA4 þ GRPs) in D-PBS containing 0.1% bovine serum albumin (BSA) were loaded on the inlet of the microfluidic device. A 20Â objective with a field of view of 950 Â 725 mm 2 was used to monitor cell binding under shear flow. Each perfusion experiment lasted 3 min. Cell velocities were determined by dividing the distance the cell traveled during cell-substrate interaction by the time for each tested condition. 41 
Preparation of microfluidic devices coated with endothelial cells
A pre-cleaned glass slide and a microfluidic device were plasma-treated for 2 min and adhered together to create a seal. Channels were perfused with 20 mg/ml fibronectin (Sigma) and incubated for 1 h at 37 C. Fibronectin was removed by washing with D-PBS. Human brain endothelial cells (HBEC, 2 Â 10 6 cells/ml) were perfused into the channels and incubated at 37 C for 48 h, with changing of media every 12 h to allow adhesion of HBECs. Twenty-four hours prior to the onset of the flow experiments, endothelial cells were activated by exposure to 40 ng/ml TNFa (Cell Signaling Technology).
Chemotaxis migration assay
A migration assay was performed in chemoattractant gradient-generating devices fabricated as described previously. [42] [43] [44] A total of 50 mL of 5 Â 10 6 cells/ml was added to the inlet of the microfluidic device. Cell migration was visualized using a bright-field microscope (Nikon, Japan) every 20 min for 16 h with the NIS-Elements software. Migration velocity was analyzed using the NIS-Elements add-on Tracking module. Data represent the mean AE S.D. values of five independent experiments.
Induction of stroke model
Experiments were performed in accordance with guidelines for the care and use of laboratory animals approved by the Institutional Animal Care and Use Committee of Johns Hopkins University, designed in compliance with the Animal Welfare Act regulations and Public Health Service (PHS) Policy. All animal experiments were approved by The Johns Hopkins Institutional Animal Care and Use Committee and were in compliance with ARRIVE guidelines. Ischemia was induced in adult male SVE 129 and NOD-SCID mice (Jackson Labs) using a transient middle cerebral artery occlusion (MCAO) model. 45 Animals were housed in the Johns Hopkins School of Medicine animal facility in standard cages with filter tops, with a 12:12 light:dark cycle, controlled humidity and temperature conditions, and with ad libitum access to water and food. Briefly, animals were anesthetized with 1-2% isofluorane in oxygen-enriched air using a face-mask. A small scalp incision was made and a small parietal burr hole was made with a low-speed drill until a thin amount of bone remained. A small laser Doppler probe (Moor Instruments, USA) was held against the bone for cerebral blood flow measurements. The right common carotid artery was exposed through a side neck incision. The right external carotid artery was ligated proximal to the occipital artery, the occipital artery was cauterized, and the pterygopalatine artery was ligated. An incision was made in the common carotid artery distal to the ligation and an occluding filament was advanced into the internal carotid artery (ICA) to the origin of the MCA, a point at which the laser Doppler signal abruptly drops. Reduction of signal was 70% of baseline and the MCAO was maintained for 1 h, after which the neck incision was closed with sutures.
IA infusion of GRPs
One day after MCAO, animals were anesthetized with 1-2% isofluorane in oxygen-enriched air using a facemask. The right ICA was exposed through a side neck incision. Animals were randomly assigned to control (naı¨ve GRPs; n ¼ 5 for 2PM study and n ¼ 3 for longterm 30-day follow-up study) and experimental (VLA4 þ GRPs; n ¼ 5 for 2PM study and n ¼ 3 for long-term 30-day follow-up study) groups. A dedicated mouse carotid artery catheter (Instech) was placed in the ICA and its position was fixed with two sutures. Cell infusion was performed after placing anesthetized animals in a custom-made frame during the course of 2-PM. The cell suspension (1 Â 10 6 cells in 200 ml PBS) was infused over 5 min using an automated infusion pump.
Intravital 2-PM
All animal procedures were reviewed and approved by the Johns Hopkins Animal Care and Use Committee. Intravital imaging was performed with an Olympus FV1000MPE multiphoton laser-scanning microscope. On the day of imaging, animals were anesthetized with 1-2% isofluorane in oxygen-enriched air. A small scalp incision was made and a skull window (2 Â 2 mm 2 ) was made above the right hemisphere with a high-speed drill. The exposed brain was cleaned with saline to remove any blood. A custom-made head post was cemented to the skull and the animal was placed in a custom-made frame to eliminate respiratory motion. TexasRed conjugated dextran (Mw ¼ 70 kDa, Life Technologies) was injected via an ICA catheter 10 min before cell infusion to visualize blood vessels. GRPs were then injected over 1 min and the selected field of view was imaged every 10 min for 3 h (n ¼ 5 for the control and experimental groups). After imaging, animals were sacrificed and brains were collected for further analysis.
Histopathological analysis
After intravital imaging, mice were perfused with 4% PFA. Brains were removed and cryopreserved in 20% sucrose for 48 h, frozen on dry ice, and cryosectioned as 20 mm coronal sections. Tissue sections were examined with an Axio Vert inverted microscope and tiling module (Zeiss). The number of green fluorescent cells (CMFDA-labeled) in the ipsilateral hemisphere was counted for both the experimental and control groups (n ¼ 5 each), with four random brain slices each, resulting in a total number of 20 counts per group.
NOD-SCID animals transplanted with naı¨ve or VLA4 þ GRPs were sacrificed 30 days after cell transplantation. Animals were perfused with 4% PFA, brains were removed, cross-sectioned at 20 mm, and processed for fluorescence microscopy. Tissue sections were imaged with an Axio Vert inverted microscope to detect GFP-expressing transplanted GRP cells.
Statistical analysis
Data are presented as mean AE 95% confidence interval (CI) for n ! 4 independent experiments. The statistical significance of differences between groups was tested with a non-parametric Kruskal-Wallis test for the comparison of multiple groups (transfection efficiency, microfluidic assays) or the Mann-Whitney test for pairwise comparison of naı¨ve and VLA4
þ GRPs groups (microfluidic assays, migration assay, and histopathology). All calculations were performed using Prism 3.0, with p < 0.05 considered significant. To identify minimum differences (considered as clinically relevant), the Hedges' g factor was calculated. For this exploratory study, all tests were two-sided, with no further adjustment for multiple comparisons.
Results
Characterization of VLA-4 þ GRPs
Expression of both the a4 and b1 integrin subunits in transfected GRPs was confirmed with RT-PCR and immunocytochemistry. Immunostaining showed that 66% and 70% of the cells were positive for integrin a4 and b1 subunits, respectively (Figure 1(a) and (b) ). Non-transfected GRPs were negative for the expression of both VLA-4 subunits. VLA-4 expression did not affect the differentiation of GRPs toward mature oligodendrocytes, as demonstrated by the presence of the mature oligodendrocyte marker MBP at the mRNA and protein levels (Figure 1(d) ).
Binding of VLA-4 þ GRPs to purified VCAM-1
Overexpression of VLA-4 in GRPs resulted in a markedly higher binding capacity to the purified VCAM-1 substrate, compared to controls, accompanied by a significantly lower cell velocity attributed to the formation of VLA4-VCAM-1 bonds, resulting in more resistance to dispersive hydrodynamic shear forces. The VCAM-1-bound VLA-4
þ GRPs traveled at a speed of 17.9 (95% CI 15.6 to 20.3) mm/s, which was 72% lower than that measured for naı¨ve GRPs þ GRPs to VCAM-1 was non-static, with multiple short periods of cell arrest. Conversely, naı¨ve GRPs, a4 þ GRPs, and b1
þ GRPs bound to VCAM-1 with 74% less efficiency compared to VLA-4 þ cells (Figure 2(a) ). Evidently, transfection with both subunits of VLA-4 was necessary for cell binding and improved cell tethering to VCAM1-coated channels. We observed more than a 3-times higher number of interacting cells after the overexpression of VLA-4 (VLA-4 þ GRPs 38.2 (95% CI 27.2 to 49.2; p < 0.001, Hedges' g ¼ À3.578)) compared to naı¨ve GRPs (10.4 (95% CI 4.9 to 15.9), a4 þ GRP 8.8 (95% CI 3.6 to 13.6; p ¼ 0.159, Hedges' g ¼ 0.346) and b1 þ GRP (11.8 (95% CI 6.5 to 17.1; p ¼ 0.430, Hedges' g ¼ 0.311)) (Figure 2(b) ). Statistical analysis was performed with the KruskalWallis test.
Binding of VLA-4 þ GRPs to TNF-activated, VCAM-1 expressing HBECs
Incubation of HBEC with TNFa increased the expression of VCAM-1, as demonstrated by immunocytochemistry (Figure 3(a) and (b) ). Perfusion of cells through a microfluidic channel coated with activated HBECs showed a significantly lower (by 65%) average speed of VLA-4
þ GRPs compared to naı¨ve GRPs (Figure 3 be detected in channels coated with non-activated HBECs, with <10% differences.
Compared to naı¨ve GRPs, we observed a 4-times higher number of VLA-4 þ GRPs that bound to activated endothelial cells (VLA-4 þ GRPs 40.4 (95% CI 29.6 to 51.3) compared to naı¨ve GRPs (11.2 (95% CI 6.9 to 16.3; p ¼ 0.005; Hedges' g ¼ 9.6)) (Figure 3(d) ). Taken together, these results indicate that VLA-4 þ GRPs bind specifically to activated endothelium. Statistical analysis was performed using the Mann-Whitney test.
The effect of VLA-4-transfection on the migratory potential of GRPs
The migratory properties of both naı¨ve GRPs and VLA-4 þ GRPs were assessed using a microfluidic device with an FBS chemoattractant gradient to drive cell migration. Average cell migration velocity and migration distance into the channels were used as primary readouts. VLA-4 þ GRPs were found to migrate with moderately higher speeds compared to naı¨ve GRPs, and these differences were statistically significant (p < 0.001) in all channel widths except for the 50 -mm wide channels, where the speed was 53.4 mm/h (95% CI 43.9 to 62.9) for naı¨ve GRPs and 72.0 mm/h (95% CI 57.4 to 76.6) for VLA4 
VLA-4
þ GRPs (p < 0.001; Hedges' g ¼ 5.752) (Figure 4(a) ). There was also a difference in total distance of cell migration. For 50 mm channels, the total covered distance was higher by 37% (from 312.6 (95% CI 275.5 to 349.7) for naı¨ve cells to 429.2 (95% CI 385.7 to 472.7) for the VLA-4 þ GRP; p ¼ 0.008; Hedges' g ¼ 3.235). In the rest of the channel widths, observed differences were larger (p < 0.001), reaching 60-70% (20 mm: 257.3 (95% CI 218.7 to 295.8 mm) for naı¨ve GRPs to 480.6 (95% CI 442.4 to 518.8) mm for VLA-4 þ GRPs (Hedges' g ¼ 5.518); 10 mm: 275.4 (95% CI 225.2 to 325.6) mm for naı¨ve GRPs to 530.0 (95% CI 483.5 to 576.5) mm for VLA-4 þ GRPs (Hedges' g ¼ 5.9); 6 mm: 269.4 (95% CI 225.0 to 313.7) mm for naı¨ve GRPs to 514.0 (95% CI 472.2 to 555.7) mm for VLA-4 AE GRPs (Hedges' g ¼ 6.37)) (Figure 4(b) ). Taken together, our data reveal that VLA-4 þ GRPs migrate more efficiently in physiologically relevant confined channels and are moderately more efficient in channels resembling a 2D microenvironment when compared to naı¨ve GRPs (Figure 4(b) ). The statistical analysis was performed using a Mann-Whitney test.
Homing and diapedesis of GRPs following IA injection in an MCAO mouse model
Multiphoton microscopy of intraarterially transplanted GRPs. MCAO-induced ischemia resulted in increased expression of the VCAM-1 protein on the cerebral endothelium, as detected by immunohistochemistry. 46 Endothelial activation was very rapid, with high VCMA-1 expression detected as early as 24 h after the ischemic insult. At the same time point, IA-injected green fluorescent GRPs were found to adhere to the cerebral endothelium. Compared to naı¨ve cells, the homing of VLA-4
þ GRPs was more robust. The binding strength of transfected cells was improved, as none of the cells observed over the 3.5-h intravital imaging window detached under the pressure of blood flow. In contrast, binding of naı¨ve GRPs to endothelial cells was not only sparse, but also transient, with cells detaching during imaging and dispersing out of the field of view. Furthermore, time-lapse 2-PM identified multiple examples of infused VLA-4 þ GRPs extravasating through the blood vessel wall into the brain parenchyma (18% of cells in the field of view) ( Figure 5(a) ). None of the naı¨ve GRPs showed diapedesis and were either dispersed out from the field of view or remained immobilized inside blood vessels ( Figure 5(b) ).
Histopathologic confirmation of cell distribution. Histological detection of cells validated the imaging results, demonstrating cells in the ipsilateral hemisphere. For each analyzed region of interest, there were an average of 304.6 (95% CI 234.9 to 374.3) VLA-4 þ GRPs and 83.0 (95% CI 24.38 to 141.6) of naı¨ve GRPs, indicating an over three-fold higher number of docked cells for VLA-4 þ compared to naı¨ve GRPs (p < 0.001; Hedges' g ¼ 3.881) (Figure 5(c) and (d) ). The statistical analysis was performed using the Mann-Whitney test.
Discussion
The safety and feasibility of intraarterial injections have been shown in several animal studies. [47] [48] [49] [50] The transplantation of bone marrow mononuclear cells was shown to be safe in Phase I clinical trials in patients with non-acute 51 as well as acute 52 stroke. In both of these studies, no deaths, stroke recurrence, or cellmediated adverse events were observed during 6 months of follow-up. The safety of intraarterial cell delivery was also shown in Parkinson's patients, where autologous bone marrow mononuclear cells were injected close to the affected area of the brain with the use of super-selective arterial catheterization. 53 We have previously shown that naı¨ve, immortalized GRPs do not bind to the cerebral endothelium following IA injection, even after global activation with LPS. 37 These small progenitors are not spontaneously captured in the brain and are lost in filtrating organs. In the current study, we have shown that this is also true for the primary, therapeutic GRPs, clearly indicating the need for a strategy that would facilitate their docking and diapedesis. Interestingly, it has been shown that mesenchymal stem cells (MSCs), which are quite large, with a size that exceeds that of the capillary vessels when injected intraarterially, initially localize to the brain, but that homing is transient and usually does not exceed 24 h. 30, [54] [55] [56] This data suggests that binding of transplanted cells to blood vessel walls is very weak or is based only on passive mechanical trapping in the small vasculature. To increase the efficiency of the endothelial capture of GRPs, we used the welldescribed VLA-4-VCAM-1 axis involved in the adhesion and extravasation of leukocytes. 57 Our in vitro studies demonstrate that VLA-4-expressing primary GRPs interact and transiently roll on either recombinant VCAM-1 or activated HBEC cells expressing VCAM-1. VLA-4 þ GRP cells display a rolling behavior similar to that of leukocytes, 58 confirming the functionality of the transgene. Microfluidic assays have been utilized to study the binding of numerous, functional ligand-receptor pairs, including ligand-P/-E-/L-selectin 40 and ligand-VCAM-1. 58, 59 However, these works do not directly correlate in vitro observations with in vivo results. The interactions of leukocytes with VCAM-1 have been shown to promote rolling and tethering at low shear stresses. 58, 59 Also, Vanderslice et al. have shown that the use of a small molecule agonist, which can up-regulate the activity of the a4/b1 heterodimer, greatly enhances the adhesion of Jurkat and endothelial progenitor cells to VCAM-1 under static and flow conditions in a plate, flow-chamber assay. These authors also showed spreading and migration of both kinds of cells after treatment with the VLA-4 agonist. 60 VLA-4 has also been demonstrated to be involved in the migration of cells. It has been shown that the binding of the heterodimer a4/b1 to fibronectin is necessary and sufficient to promote directional cell migration. 61 This is in agreement with results obtained by us from in vitro studies with the use of a microfluidic channel migration assay, where VLA-4 þ GRPs migrate with higher speeds and travel further than naı¨ve cells. The in vivo VLA-4 expression and the migratory abilities of human melanoma cells have been correlated. Highly metastatic tumor cells were found to express integrins a4/b1 at a high level, whereas non-metastatic melanoma cells displayed a low expression. 62 This indicates that the VLA-4-VCAM-1 axis is not restricted to leukocytes, but can be involved in the migration and diapedesis of other cell types. Here, utilizing in vitro flow-based assays allowed us to verify binding partners using less invasive modes, while still achieving physiologically relevant flow and binding conditions, before proceeding to in vivo validation of VLA-4 þ GRPs. After the transplantation of engineered progenitors in an MCAO model of stroke, we observed a significant increase in the number of cells homing to the area of injury. With intravital multi-photon microscopy, we showed a four-fold increase in the number of adhered cells and these observations were validated by histopathology. Although endothelial capture of the transplanted cells is important, and perhaps, sufficient in the case of a paracrine trophic effect, if glial progenitors need to be in close proximity to axons, diapedesis into the brain parenchyma is critical. Several papers have reported some level of migration of the transplanted cells through blood vessel walls after their intravascular delivery. In a rat model of stroke, for the first 24 h after intraarterial injection, MSCs were found inside blood vessels; however, after 10 days, a small number of cells had transmigrated into the brain parenchyma. 31 In another intraarterial delivery study with mannitol-mediated blood-brain barrier disruption, 15% of transplanted pericyte progenitor cells were observed outside the vasculature in the brain parenchyma. However, the majority of cells persisted on the activated endothelial cells in the vessels. 63 Other reports have indicated that intraarterially transplanted cells do not migrate to the brain tissue at all, but remain in the blood vessel lumen. 48, 54 In this context, increasing the diapedesis of transplanted cells is an important issue that warrants further investigation. In the current study, homing of the transplanted cells into injured tissue was observed only after the overexpression of VLA-4. During intravital microscopy, 15% of transplanted cells expressing the integrins a4/b1 migrated through blood vessel walls into the brain parenchyma. The VLA-4/VCAM-1 axis and its role in the diapedesis of transplanted cells have been described by Gavina and co-workers. They showed that the migration of CD133þ stem cells from the vasculature to muscle tissue is dramatically reduced by the VCAM-1 blocking antibody. 64 Another elegant example of manipulating cell trafficking was the intravenous injection of VLA-4-expressing CD34þ cells in tumorbearing mice. Transplanted cells effectively homed to the tumor (both vascular and parenchymal) and the a4/b1 integrin inhibitor significantly reduced that homing. 65 A similar involvement of the VLA-4/ VCAM-1 axis in the homing of stem cells was shown by Brunner and co-workers in virus-induced dilated cardiomyopathy (DCM) where blocking of the VCAM-1 significantly reduced stem cell migration toward the injury and remodeling of the injured heart tissue. 66 The GRP cells used for this study were extensively tested in animal models and were found to be safe and of high therapeutic potential, 16, 17, 67 thus clearing a path for their clinical use. Although GRPs are isolated from human fetal brain tissue, and access to that tissue is obviously limited, their potency and safety makes them ideal candidates for initial studies on the feasibility of brain repair in stroke. Nevertheless, our technique of diapedesis enhancement will also be applicable for more plentiful sources of progenitors, such as induced pluripotent stem cells. 68 In conclusion, our in vitro and in vivo data demonstrate that overexpression of the VLA-4 receptor in progenitor cells, based on DNA plasmid transfection, is a promising strategy with which to increase the efficiency of cell homing after intraarterial transplantation.
Limitations
1. In two-photon microscopy, the imaging window is inherently small, facilitating the observation of only several hundred mm 2 and effective monitoring of only a few cells in the field of view. Tomographic techniques suitable for large-scale imaging, such as MRI, are available; however, the sensitivity and resolution are not suitable for the visualization of diapedesis.
2. Homing of IA-injected cells to the cerebral vasculature and their diapedesis toward the brain parenchyma were higher in VLA-4-overexpressing cells; however, the number of cells that migrated to the brain parenchyma remained small and further improvement of transfection efficiency is needed to facilitate therapeutic applications. As an alternative strategy, the use of mRNA seems to be more promising. mRNA does not carry the risk of insertional mutagenesis and it is also highly effective in nondividing or primary cells. These qualities make mRNA-based cell engineering highly attractive, particularly for clinical use. [69] [70] [71] 3. This work does not include an assessment of the therapeutic effect or functional benefits on stroke-injured mice that is elicited by transplanted progenitors, but was rather focused on improving the endothelial capture and diapedesis of glial progenitor cells 
